SVCP
RVNC

Silicon Valley Capital Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Silicon Valley Capital Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-135,788
Closed -$349K – 331
2024
Q2 		$349K Buy
+135,788
New +$464K 0.05% 62

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Silicon Valley Capital Partners's RVNC Position: Q3 2024 in Review

Silicon Valley Capital Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 135,788 shares — an estimated $349K sold.

Silicon Valley Capital Partners first reported a position in RVNC in Q2 2024 and held it in 1 quarter. The position peaked at $349K in Q2 2024. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Silicon Valley Capital Partners reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Silicon Valley Capital Partners sold 135,788 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $349K.
  • Silicon Valley Capital Partners first reported a position in Revance Therapeutics, Inc. in Q2 2024 and held it in 1 quarter.
  • Silicon Valley Capital Partners's Revance Therapeutics, Inc. position peaked at $349K in Q2 2024.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Silicon Valley Capital Partners's 13F filing for Q3 2024, filed 30 Oct 2024.